Ann: Mesoblast Update on COVID-19 ARDS Trial, page-354

I wonder how do we ever design clinical trials that are fair from now on? the goalpost keeps on moving as new treatments become available at an accelerated rate, putting the crazy ambitious 43% reduction in mortality aside.

NON of the treatments for ARDS has succeeded (perhaps apart from dexamethasone), which again would have been used on these patients MSB was treating, + all other anti-TNF, anti-IL6, anti-viral, that the patients are likely given. We can't foresee what will counteract/reduce the potency of MSCs (if any, but anti-TNF is a prime candidate). HOW do we ever design a trial like this if the "placebo/SOC" keeps on changing??

disappointed, YES, but still believe in the SCIENCE, if stem cells can't reduce inflammation in such a complex disease, I can't think of anything that could. I hope Norvatis sees this, and see the value in saving 60% of patients in HF class II.